New “science advisory” on ADT and cardiovascular risk

The American Heart Association, the American Cancer Society, and the American Urology Association have come together to issue a joint “science advisory” on androgen deprivation therapy (ADT) and cardiovascular risk. The document has also been endorsed by the American Society for Radiation Oncology. … READ MORE …

Hormone therapy, radiotherapy, and risk for cardiovascular mortality

An article in this week’s Journal of the American Medical Association has gained a great deal of media attention because it links hormone therapy in prostate cancer patients to a risk for death in patients with pre-existing cardiovascular disorders. The “New” Prostate Cancer InfoLink feels that it should emphasize that the outcomes reported in this study are actually not surprising at all. The risk of cardiovascular mortality associated with hormone therapy in men with prostate cancer  is well known and well understood. What is surprising to us is that these men were ever exposed to hormone therapy under the circumstances described! … READ MORE …

Prostate cancer news update: Tuesday, 9 September

This morning’s news update deals with two newly published studies:

  • The relative effectiveness of two different types of artificial sphincter for the chronically incontinent post-treatment
  • The impact of ADT on metabolic and cardiovascular processes and the risk for significant adverse reactions as a consequence of hypogonadism … READ MORE …